Though lung cancer looks promising a partner is now needed.
ApexOnco Front Page
Recent articles
Deteriorating efficacy and a treatment-related death with Zynlonta plus Columvi spook investors.
The agency approved eight oncology products over the month.
The group will take HRS-4642 into a Chinese phase 3 in first-line pancreatic cancer.
Varegacestat’s pivotal study reads out imminently.
The pivotal Harmoni-GI3 study has started enrolling patients.
ASH and SABCS approach.
Readout of the Preserve-003 trial in post-PD-(L)1 NSCLC is due in December.
